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INTRODUCTION 
Aminoglycosides were first introduced in 1945 with 
the development of s t r e p t o m y c i n . Almost immediately the 
first case reports of ototoxicity were described in 
patients receiving the drug for t u b e r c u l o s i s .
1
 The 
potential to p r o d u c e both vestibular and auditory 
toxicity became widely known effects of the use of all 
of the subsequently developed a m i n o g l y c o s i d e s . Although 
this toxicity has been known for greater than forty 
y e a r s , u n d e r s t a n d i n g the factors that influence the 
incidence and extent of ototoxicity still require 
extensive s t u d y . It remains unclear what places an 
individual most at risk for developing this t o x i c i t y . 
Exactly which parameters to monitor are d e b a t e d , and the 
utility of such m o n i t o r i n g q u e s t i o n e d .
2
 Much attention 
has been placed on m e a s u r i n g aminoglycoside serum 
concentrations and establishing a therapeutic range to 
both ensure efficacy and prevent both ototoxicity and 
n e p h r o t o x i c i t y . 
The state of the art in m o n i t o r i n g ototoxicity 
stands in sharp contrast to the m o n i t o r i n g of 
n e p h r o t o x i c d a m a g e , w h e r e serum c r e a t i n i n e , creatinine 
clearances and serum concentrations of the agent are 
routinely m e a s u r e d . M e a s u r e m e n t s of effects of these 
drugs on both cochlear and vestibular function are not 
routinely u t i l i z e d . 
2 
Part of the reason for this is that tests needed to 
detect otological damage are both time consuming and 
often logistically impossible in critically ill 
p a t i e n t s . F u r t h e r m o r e , p r e v i o u s l y , there has not been a 
tool that is sensitive enough to always detect early 
o t o t o x i c i t y . To illustrate this point some background 
information concerning the effects of aminoglycosides on 
the ear are n e c e s s a r y . Only cochlear toxicity will be 
discussed as this is the focus of the present study. 
Cochlear toxicity is thought to be a result of 
aminoglycoside damage to the outer and inner sensory 
hair cells of the organ of C o r t i . H i s t o l o g i c a l l y , this 
damage has been described in both guinea pigs and humans 
as occurring initially at the base of the cochlea and 




Clinically this is represented by elevation of hearing 
thresholds in the h i g h - f r e q u e n c i e s with a progression 
into the lower f r e q u e n c i e s . T r a d i t i o n a l l y in human 
a u d i o l o g y , low to mid frequencies are designated as 
those between 125 Hz and 2000 Hz. High frequencies have 
been considered to be 2000 Hz to 8000 Hz, and 
frequencies above this are extended high f r e q u e n c i e s . 
Conventional audiometry evaluates frequencies from 250 
Hz through 8000 H z . In a review of the detection of 
ototoxicity using h i g h - f r e q u e n c y auditory e v a l u a t i o n , 
Rappaport and colleagues report that the p a u c i t y of 
literature in this area is due to the lack of a 
reproducible test for pure-tone thresholds in the 
frequencies above 8000 H z .
5
 In a u d i o l o g y , a hearing 
threshold is defined as the lowest sensation level at 
which sound for a particular frequency is detected by an 
individual 50 percent of the time. 
The precise mechanism by which aminoglycosides 
produce hearing loss has not been completely e l u c i d a t e d , 
although several theories have been proposed and 
reviewed. The most widely accepted theory is that 
proposed by Schacht et al. which postulates that the 
hair cell destruction is due to the effect on cellular 




 Weiner and Schacht summarized 
their findings in 1981 which pointed to the b i n d i n g of 
aminoglycosides to p o l y p h o s p h o i n o s i t i d e s as the site of 
toxic a c t i o n .
8
 The p o l y p h o s p h o i n o s i t i d e s are peptides 
involved in the regulation of cellular membrane 
stability and p e r m e a b i l i t y . Weiner and Schacht 
demonstrated that aminoglycosides alter cellular 
permeability and ion transport through competitive 
inhibition at low c o n c e n t r a t i o n s and noncompetitive 
inhibition at higher c o n c e n t r a t i o n s . R e c e n t l y , 
Tachibana et al. performed b i n d i n g studies with a 
neomycin-gold colloid complex to show h i s t o l o g i c a l l y 
that neomycin binds to t r i p h o s p h o i n o s i t i d e s in the cell 
membranes and the nervous elements of the c o c h l e a .
9 
4 
This research group also reported binding of 
aminoglycosides to g l y c o s a m i n o g l y c a n s in the connective 
tissues and tectorial leibrane which may be histological 
evidence for other proposed mechanisms of cochlear 
toxicity in addition to m e m b r a n e permeability 
alteration. The extent to which these effects occur 
partially depends on the concentration of aminoglycoside 
in the p e r i l y m p h , which is the fluid that fills the 
scala tympani and scala v e s t i b u l i , allowing for direct 
contact with the organ of C o r t i .
1 0 
Federspil provides an analysis of the 
pharmacokinetics of aminoglycosides in p e r i l y m p h . He 
found that by administering p r o g r e s s i v e l y larger 
systemic doses of aminoglycoside the concentration in 
perilymph increased in a linear f a s h i o n .
1 1
 Federspil 
also demonstrated in the animal model that the terminal 
half-life of gentamicin in the perilymph was the same 
after chronic administration as it was after a single 
d o s e .
1 1
 This suggests that fluctuation in serum 
c o n c e n t r a t i o n s , such as high p e a k s , does not contribute 
to accumulation in the perilymph and therefore may not 
directly affect the rate or extent of t o x i c i t y .
1 1 
From these f i n d i n g s , Federspil p o s t u l a t e d that the 
total dose of a m i n o g l y c o s i d e a patient receives is 
associated with the degree of cochlear d a m a g e .
1 2
 Human 
clinical studies done in B a l t i m o r e on aminoglycoside 
5 
ototoxicity further support this a s s o c i a t i o n .
1 2
 One 
hundred thirty-five patients were studied for their 
relative risk of both reversible and irreversible 
auditory toxicity from aminoglycoside therapy. Using 
conventional a u d i o m e t r y , toxicity was ascribed if the 
patient had a loss of greater than or equal to 15 dB at 
any one f r e q u e n c y , determined by the comparison of pre-
and post treatment a u d i o g r a m s . They found a 22.3* 
incidence of o t o t o x i c i t y . Duration of therapy, total 
aminoglycoside dosage and b a c t e r e m i a reached statistical 
significance as discriminators between the ototoxic and 
non-ototoxic g r o u p s . 
Toxic a m i n o g l y c o s i d e c o n c e n t r a t i o n s in the 
perilymph alone do not completely explain the 
occurrence or extent of o t o t o x i c i t y . Studies have 
demonstrated that netilmicin and gentamicin are present 
in the same c o n c e n t r a t i o n in perilymph of guinea pigs 
and that their elimination rate is e q u i v a l e n t , but they 
do not p r o d u c e the same incidence of t o x i c i t y .
1 2 
Wers&ll d e m o n s t r a t e d that tobramycin in doses of 
lOOmg/kg given for 18 days to guinea pigs produced more 
hair cell damage than t h e r a p e u t i c a l l y equivalent 
netilmicin given at the same d o s a g e .
1 3
 This has also 
been shown for netilmicin when compared to amikacin and 
g e n t a m i c i n .
1 4
 In comparison to these animal s t u d i e s , 
results from human studies have been more c o n t r o v e r s i a l . 
6 
Wers&ll reviewed the human comparative studies with the 
individual aminoglycosides and found problems in 
m e t h o d o l o g y , including not c o n t r o l l i n g for a g e , 
underlying disease and varying criterion for determining 
o t o t o x i c i t y .
1 5
 This renders comparisons of relative 
toxicities between the aminoglycosides d i f f i c u l t . The 
varying extent to which the individual aminoglycosides 
bind to various structures in the cochlea has not been 
adequately investigated but could provide helpful clues 
in determining relative ototoxic p o t e n t i a l s . 
Another d i f f i c u l t y in assessing aminoglycoside 
ototoxicity has been the lack of a clinically useful 
tool to measure pure tone h e a r i n g thresholds at 
frequencies greater than 8 k H z . New calibration and 
instrumentation techniques have aided in the development 
of high frequency a u d i o m e t e r s . F a u s t i , in 1979, 
developed a technique that overcame some of the 
calibration concerns and still allowed for earphone 
t e s t i n g .
1 6
 Since then a new high frequency audiometer 
with which r e p r o d u c i b l e hearing thresholds can be 
obtained has become a v a i l a b l e .
1 7
 Test-retest studies 
demonstrate that there is reliability in achieving 
reproducible results with this audiometer in clinical 
p r a c t i c e .
1 8
 Studies e s t a b l i s h i n g normal values have 
been performed but the firm establishment of the 
definition of normal hearing has not yet been 
7 








 This is partly due to varying 
methodology and instrumentation and is also largely due 
to the small numbers of ears tested to d a t e .
2 2
 A 
criterion for defining hearing loss secondary to 
ototoxicity is still debated due to a lack of normative 
data. N e v e r t h e l e s s , h i g h - f r e q u e n c y audiometry is 
beginning to be used as a clinical tool for early 
detection of o t o t o x i c i t y . 
Using the calibration technique developed by 
Fausti, Dreschler et al. tested 100 ears of patients 
before and after receiving platinum derivatives and 
demonstrated a 68* incidence of hearing loss in the 
frequency range greater than 8 k H z , compared to a 44* 
incidence if only conventional audiometry had been 
u s e d .
2 3
 They defined hearing loss for their study as a 
threshold shift of 15 dB or more at any two f r e q u e n c i e s , 
or 20 dB at one f r e q u e n c y . These findings support the 
use of h i g h - f r e q u e n c y audiometry in the early detection 
of hearing loss from ototoxic agents that initially 
insult the basal portion of the c o c h l e a . 
OBJBCTIVB 
The p u r p o s e of this investigation was to evaluate 
cumulative effects of aminoglycoside therapy on high-
frequency hearing t h r e s h o l d s . S p e c i f i c a l l y , the study 
evaluated whether or not differences in hearing 
8 
thresholds could be detected between patients known to 
have received chronic aminoglycoside therapy versus 
those who have had no known exposure to ototoxic 
stimuli. This study design was similar to other 
investigations into noise-induced hearing loss in that 
one time audiograms of the patients were compared to 




A large number of cystic fibrosis patients are seen 
at the University of Utah and were considered an ideal 
population for an aminoglycoside ototoxicity study for 
many r e a s o n s . Patients with cystic fibrosis represent a 
relatively uniform population in terms of presentation 
of disease and the type of medical therapy r e q u i r e d . 
Lung involvement accounts for greater than 95 percent of 
mortality associated with this d i s e a s e .
2 6
 The bacterial 
pneumonias which occur almost e x c l u s i v e l y progress to 
involve Pseudomonas aeruginosa which is often 
susceptible to a m i n o g l y c o s i d e s . The majority of older 
cystic fibrosis patients therefore have required 
repeated therapy with these a g e n t s . C y s t i c fibrosis 
patients also represent a relatively young p o p u l a t i o n , 
with the median life-span equal to about 19 years of 
age, and are a c c o r d i n g l y less likely to have other 
reasons for h e a r i n g loss which would have excluded them 
from this s t u d y . A d d i t i o n a l l y , they are an ambulatory 
group in g e n e r a l , which allows for convenience in 
9 
testing h e a r i n g . Finally, access to their complete 
•edical records was possible in most cases because many 
of the patients have received treatment at the same 
institution for their entire life. 
The purpose of this study was to identify any 
difference in mean hearing thresholds of cystic fibrosis 
patients who have received aminoglycosides repeatedly, 
when compared to those patients with cystic fibrosis who 
have not received any aminoglycoside and as compared to 
normal healthy v o l u n t e e r s . There is no evidence in the 
literature or by clinical observation to believe that 
hearing thresholds are different between individuals 
with cystic fibrosis and the rest of the p o p u l a t i o n . 
This comparison was performed b e c a u s e the incidence of 
ototoxicity secondary to a m i n o g l y c o s i d e treatment has 
not been adequately investigated in this p o p u l a t i o n . 
PATIENTS AND M E T H O D S 
Patients who were seen at the cystic fibrosis 
clinic at the U n i v e r s i t y of Utah M e d i c a l Center were 
considered for p a r t i c i p a t i o n . All p a t i e n t s with cystic 
fibrosis older than age six w e r e considered for 
audiometric s t u d y . Responses in younger children may be 
unreliable due to inability to cooperate with testing 
p r o c e d u r e s . N o r m a l , h e a l t h y , age matched volunteers 
were used as c o n t r o l s . Subjects signed a consent form 
10 
which along w i t h our protocol was approved by the local 
institutional review b o a r d . All subjects were 
interviewed by the audiologist administering the test 
for factors known to contribute to hearing loss. This 
included history of head trauma, noise exposure, ear 
surgery, chronic ear infections, premature birth or 
fanily history of h e a r i n g loss. Only patients with a 
negative history of severe noise exposure or positive 
history of minor exposure followed by normal hearing 
thresholds at frequencies less than 8000 Hz that did not 
reflect noise exposure were used in the s t u d y . Patients 
whose medical histories were unknown or in question were 
also excluded from the i n v e s t i g a t i o n . A time period of 
at least two weeks from the last course of 
aminoglycoside therapy to the audiometric exam was 
required to reduce the detection of reversible toxicity. 
The test site was the University of Utah 
Otolaryngology Clinic IAC model 403 sound-treated b o o t h . 
Ambient noise levels were m e a s u r e d with a Larsen-Davis 
model 800B sound level meter and were well within the 
levels specified by the American National Standards 
Institute (ANSI) S C . 1 - 1 9 7 7 .
2 7
 These standards are not 
applicable to frequencies higher than 8000 Hz, but there 
was no m e a s u r a b l e ambient noise in the frequencies above 
8000 H z . The test equipment included an Amplaid model 
702 impedance b r i d g e , a G r a s o n - S t a d l e r model 1704 
11 
clinical a u d i o m e t e r , and a Demlar model 20,000 Hz high-
frequency a u d i o m e t e r . The G r a s o n - S t a d l e r audiometer was 
equipped with TDH-39 earphones in MX-41/AR cushions and 
was calibrated to ANSI S.3-1969 s t a n d a r d s .
2 8
 The Demlar 
audiometer was equipped with Koss model HV/1A earphones 
for which there are no ANSI specifications for 
c a l i b r a t i o n . The calibration for these earphones 
insured that the output at each f r e q u e n c y , in terms of 
dB s o u n d - p r e s s u r e - l e v e l (SPL), was the same as dial 
v a l u e . Frequency was measured and found to be within 3% 
of dial value. All calibration was accomplished using 
the Larson-Davis model 800 sound level meter (SLN) and 
associated 1/2 inch m i c r o p h o n e , and the coupler 
described by Fausti et a l .
1 8
 C a l i b r a t i o n was checked 
approximately every two months throughout the course of 
this study to insure accuracy of the s t i m u l i . 
To avoid any contamination of the data as a result 
of an underlying outer or middle ear d y s f u n c t i o n , an 
otoscopic examination was performed followed by 
tympanometry and acoustic reflex t e s t i n g . Cerumen that 
obstructed v i s u a l i z a t i o n of the tympanic membrane was 
removed by an o t o l a r y n g o l o g y r e s i d e n t . Patients with 
abnormal tympanograms or absent acoustic reflexes were 
rescheduled for testing at a later d a t e . 
12 
Pure-tone air-conduction thresholds were determined 
in both ears at 250 H z , 500 Hz, 1000 Hz,2000 Hz,3000 Hz, 
4000 Hz, 6000 Hz, and 8000 Hz, using the conventional 
audiometer. Thresholds at frequencies from 8000 Hz to 
20,000 Hz were determined at 1000 Hz intervals using the 
Demlar a u d i o m e t e r . ( A p p e n d i x I) All thresholds were 
obtained using the p r o c e d u r e recommended by Carhart and 
J e r g e r .
2 9
 Bach subject was given conventional 
audiometric instructions and all audiometric testing was 
done by one of two professional audiologists holding the 
Certificate of C l i n i c a l C o m p e t e n c e from the American 
Speech-Language-Hearing A s s o c i a t i o n . 
Descriptive statistics were used to represent the 
data. Paired t-tests were performed to evaluate any 
difference between the left and right e a r s , such that 
the data could be represented together if there was no 
difference n o t e d . A level of confidence of 99* was 
used. Tests of significance were performed for each 
frequency where the number of subjects in each group was 
greater than ten. Since normal distribution is unlikely 
with a small number of s u b j e c t s , n o n - p a r a m e t r i c tests 
were utilized with a level of confidence of 9 5 * . 
Subjects whose hearing threshold exceeded the maximum of 
the audiometer at any frequency were assigned a value of 
99 dB for that f r e q u e n c y . For each frequency the number 
of ears that were assigned this value were r e c o r d e d . 
13 
RESULTS 
Thirty-eight patients with cystic fibrosis were 
evaluated a u d i o m e t r i c a l l y . Three patients were excluded 
from statistical analysis of hearing thresholds. One 
was excluded due to known concurrent severe noise 
exposure, one due to asymmetric loss in high frequencies 
in the left ear from unknown c a u s e s , and one due to 
persistently abnormal tympanometry after tympanic 
p e r f o r a t i o n . Thirty-eight normal subjects were s t u d i e d . 
None of the subjects used as controls had a history of 
hearing loss, head trauma or severe noise e x p o s u r e . The 
majority of the normal subjects worked at the hospital 
or were children of employees and were not considered 
experienced l i s t e n e r s . The patients and subjects were 
divided into six groups for analysis of effects of a 
positive history of aminoglycoside exposure on hearing 
threshold. Cystic fibrosis patients were divided into 
four groups based on the presence or absence of 
aminoglycoside exposure and age less than or greater 
than 20 years. Normal subjects were divided into two 
groups based on a g e . The mean age and number of 
patients and subjects per group is p r e s e n t e d in Table A. 
It should be noted that there were only three subjects 
in the cystic fibrosis group that had not received 
aminoglycosides and were older than 20 y e a r s . 
14 
The Students p a i r e d , two-tailed t-test was 
performed using trimmed means to detect any difference 
between the left and right ear (Appendix II). A 
difference was noted at the 13,000 Hz frequency in the 
normal group, (p < 0 . 0 1 ) . Because no other differences 
were n o t e d , the data is represented with results from 
both ears c o m b i n e d . The mean hearing thresholds and 
standard deviations for each frequency are presented in 
Tables B l - 4 , categorized by group. 
A comparison of the differences between groups was 
performed with one-tail M a n n - W h i t n e y U  tests. To avoid 
the p o s s i b i l i t y of detecting a difference between groups 
at any frequency by chance alone from performing 
multiple tests, we limited the number of frequencies at 
which a comparison was m a d e . Subject groups were 
compared at 4000 Hz, 6000 H z , and 8000 Hz measured with 
the G r a s o n - S t a d l e r a u d i o m e t e r . Using the Demlar high-
frequency audiometer groups were compared at 16,000 Hz, 
17,000 Hz, 18,000 H z , 19,000 Hz, and 20,000 H z . These 
particular frequencies were chosen to compare the 
likelihood of finding elevations in h e a r i n g thresholds 
between the two ranges of audiometry t e s t i n g . 
15 
There were no differences noted between cystic 
fibrosis patients who had not received drug therapy and 
the normal subjects when this test was applied to the 
data from the younger age group.(Table C) The data from 
the two groups were then combined and compared to those 
who had received d r u g . As displayed in Table D, 
differences were noted at the four highest frequencies 
in the younger age group (p <0.005), but not in the 
lower f r e q u e n c i e s . 
In the older age group there was an insufficient 
number of patients in the cystic fibrosis group who had 
never received aminoglycosides to perform inferential 
statistical analysis with this group s e p a r a t e l y . The 
patients were combined with normal subjects older than 
20 years of age and compared to those who have received 
aminoglycoside to detect any s t a t i s t i c a l l y significant 
elevation in h e a r i n g t h r e s h o l d . The data were compared 
at the same frequencies as those listed with the younger 
age group. Differences were noted at all frequencies as 
represented in Table E . The level of s i g n i f i c a n c e was 
less than 0.001 at all of the lower frequencies and at 
16,000 Hz and 17,000 H z . The differences at frequencies 
18000 Hz through 20,000 Hz reached significance at 
0.005. 
16 
Table F refers to the number of patients who did 
not hear at the maximal output of the audiometer at 
various f r e q u e n c i e s . For all f r e q u e n c i e s , the number of 
patients who did not hear was greater in the groups who 
had received drug versus those who had not received 
drug. This is true for all frequencies except 19,000 Hz 
and 20,000 Hz in the older age group. In the older age 
group which had received drug, two patients had hearing 
deficits that extended into the frequencies below 15,000 
Hz. Both had received prolonged courses of tobramycin 
extending 4 months in one and at least 9 months in the 
other. 
Only one cystic fibrosis patient was noted to have 
a course of another possibly ototoxic agent. This 
patient had received one dose of furosemide one year 
prior to the a u d i o g r a m , and had slightly elevated 
hearing thresholds when compared to normals in the high 
frequencies above 8000 Hz. The s i g n i f i c a n c e of this is 
not k n o w n . 
DISCUSSION 
There are limited data for normal hearing 
thresholds in the frequencies above 8000 Hz using the 
Demlar a u d i o m e t e r . Laukli and Mair used thirty medical 
students ages 20 to 24 for their normative d a t a .
1 8
 They 
found that some of their subjects did not respond to 
17 
the 120 dB SPL maximal output of the audiometer, at 
frequencies above 16,000 Hz. This is consistent with 
the present f i n d i n g s , although our maximal output was 
set at 100 dB S P L . Laukli and Mair did not report mean 
and standard deviations for thresholds in this group, 
however it appears that their findings were similar to 
ours. 
In 1979, Osterhammel and O s t e r h a m m e l , used a 
different method of determining high frequency 
thresholds. They incorporated a quasi-freefield 
technique in a soundproof b o o t h , tested the hearing of 
286 normal s u b j e c t s , 67 between the ages of 10 and 19, 
and 44 between the ages of 20 and 2 9 .
2 1
 H i g h - f r e q u e n c y 
mean thresholds for their 10 to 19 year old age group 
were in good agreement with the finding of this study. 
The standard deviations ranged from 6.6 dB to 19.5 dB 
compared to our range of 5.9 dB to 21.7 dB, (see 
Table A). Note that the small standard deviations may 
be an erroneous finding in the highest frequencies 
because a large p e r c e n t a g e of patients did not hear at 
the maximal o u t p u t . The means and standard deviations 
for the older age group are also consistent with the 
present findings, with standard deviations ranging from 
6.8 dB to 16.4 dB compared to 4.9 dB to 21.1 dB in this 
study. 
18 
Pedersen et al. used the data from the Osterhammel 
study to compare the chronic effects of tobramycin in 
cystic fibrosis p a t i e n t s .
3 0
 Forty-six patients with 
cystic fibrosis were evaluated a u d i o m e t r i c a l l y using the 
same technique as they used in their normative study. 
Their criterion for determining h e a r i n g loss with one 
audiometric exam was not defined and it was not 
indicated w h e t h e r or not they s t a t i s t i c a l l y compared the 
two groups to detect d i f f e r e n c e s . They found two 
patients who had hearing loss that was attributed to 
tobramycin t h e r a p y . Of n o t e , these two patients are the 
only patients found to have total hearing loss at some 
frequencies which is significantly different from 
findings in this s t u d y . It is possible that this 
discrepancy is due to the use of a lower decibel maximal 
output in this s t u d y . 
There are certain limitations inherent in this 
s t u d y . The first is the inability to attribute the 
changes we found entirely to aminoglycoside e x p o s u r e . A 
long-term p r o s p e c t i v e study that utilizes pre-treatment 
along with follow-up audiograms is n e c e s s a r y to identify 
aminoglycosides as the exclusive etiology for higher 
hearing t h r e s h o l d s . The second limitation is the 
inability to identify the extent to which 
aminoglycosides damage h e a r i n g over time. This would 
require an analysis of the total amount of each of the 
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individual aminoglycosides received along with the time 
course the drug was d e l i v e r e d . Such a study is 
currently in progress at the University of Utah Medical 
Center. T h i r d l y , the sample size of each group was 
relatively s m a l l , restricting the power of the 
statistical a n a l y s i s . Because of this it was not 
possible to s t a t i s t i c a l l y compare the older age group 
for differences in hearing t h r e s h o l d s , controlling for 
cystic fibrosis a l o n e . Finally, it is important to note 
that elevation of pure tone h e a r i n g thresholds alone 
does not define hearing loss. A l s o , since normal pure 
tone thresholds are not defined above 8000 Hz, one 
cannot say with complete certainty that the 
aminoglycoside groups had o t o t o x i c i t y . They do, 
however, demonstrate reduced hearing sensitivity in the 
extended high frequency range. 
Particularly in patients aged between 10 and 19 
years, these findings suggest that h i g h - f r e q u e n c y 
audiometry does serve as a useful tool in detecting 
early damage due to o t o t o x i c i t y . Mean and individual 
thresholds measured by conventional audiometry do not 
indicate threshold shifts in this age g r o u p . 
It is helpful to contrast these findings in the 
younger ages to those in the older age group, where 
elevations of hearing thresholds are seen at all the 
frequencies t e s t e d . For the majority of cystic fibrosis 
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patients older than 20 years of a g e , the persistance of 
pulmonary dysfunction increases the likelihood that they 
have received extensive aminoglycoside therapy. High-
frequency audiometry would seem to be less useful as an 
initial screening tool in these p a t i e n t s . 
In summary we found that patients with cystic 
fibrosis aged 10 through 19 y e a r s , who have received 
aminoglycoside have increased mean hearing thresholds in 
the f r e q u e n c i e s , 16,000 Hz through 20,000 H z . There was 
no difference in mean hearing thresholds between cystic 
fibrosis patients who had not recieved aminoglycoside 
treatment and normal healthy v o l u n t e e r s . For those 
cystic fibrosis patients older than 20 y e a r s , higher 
mean hearing thresholds for all frequencies tested were 
noted when compared to normal s u b j e c t s . 

TABLE A . Mean age and number of p a t i e n t s / s u b j e c t s 
in each group. 
GROUP number = MEAN AGE 
cystic fibrosis (C.F.) 
age 6-19 years: 
aminoglycoside 12 13.2 
no drug 10 10.4 
age 20 + years: 
aminoglycoside 10 25.4 
no drug 3 25.3 
normals 
age 6-19 years 18 11.2 
age 20 + years 20 25.5 
combined groups 
age 6-19 years: 
C . F . no drug + normal 28 
age 20 + years: 




Table B - l . Mean pure tone hearing thresholds for 
conventional f r e q u e n c i e s . Standard deviations are in 
p a r e n t h e s e s . 
CYSTIC FIBROSIS PATIENTS 
AGE (years) 6-19 6-19 >20 >20 
AMINOGLYCOSIDE 
EXPOSURE YES NO YES NO 
NUMBBR (ears) 24 20 20 6 
250 Hz (HTL) 13.8 
(6.5) 
500 Hz 11.0 
(7.2) 
1000 Hz 4.6 
(5.9) 
2000 Hz 4.2 
(6.0) 
3000 Hz 3.1 
(7.0) 
4000 Hz 2.9 
(5.9) 
6000 Hz 9.0 
(8.7) 
8000 Hz 10.6 
(8.2) 
HTL = hearing threshold 1 
13.3 15.3 14.2 
(6.1) (4.1) (3.8) 
9.0 12.8 8.3 
(6.8) (6.6) (7.5) 
3.3 10.0 3.3 
(6.0) (13.8) (4.1) 
3.0 18.2 1.7 
(7.2) (28.7) (2.6) 
1.0 16.0 7.5 
(7.9) (30.4) (6.9) 
3.5 19.7 14.2 
(6.5) (28.1) (9.7) 
6.8 28.0 25.8 
(9.6) (29.1) (15.3) 
8.5 27.0 11.7 
(9.1) (30.3) (13.1) 
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Table B - 2 . Mean pure 
conventional f r e q u e n c i e s , 
parentheses. 
tone hearing thresholds for 
































Table B-3. Mean pure tone hearing thresholds at 
frequencies above 8000 Hz. Standard deviations are in 
parentheses. 
CYSTIC FIBROSIS PATIENTS 
AGE (years) 6-19 6-19 >20 >20 
AMINOGLYCOSIDE 
EXPOSURE YES NO YES NO 
NUMBER (ears) 24 20 20 6 
8000 Hz (SPL) 23.5 
(6.0) 
9000 Hz 27. 9 
(6.7) 
10000 Hz 26. 3 
(8.6) 
11000 Hz 25 . 2 
(8.3) 
12000 Hz 27.3 
(10.7) 
13000 Hz 37. 3 
(13.6) 
14000 Hz 37. 3 
(17.9) 
15000 Hz 42. 3 
(22.2) 
16000 Hz 54 . 7 
(20.6) 
17000 Hz 67.8 
(16.6) 
18000 Hz 80.0 
(15.9) 
19000 Hz 89. 8 
(14.2) 
20000 Hz 94. 3 
(10.6) 
SPL = sound pressure level 
22. 8 4 2 . 9 21. 6 
(7. 7) (24. 4) (12. 5) 
26. 0 4 2 . 2 36. 7 
(11. 2) (30. 4) (12. 5) 
23. 5 39. 2 43. 3 
(8. 0) (31. 3) (14. 4) 
25. 5 4 2 . 6 50. 8 
(9. 2) (29. 9) (27. 3) 
28. 8 46. 1 56. 7 
(8. 7) (29. 0) (28. 2) 
33. 3 54. 1 65. 0 
(10. 7) (25. 9) (27. 4) 
32. 0 5 9 . 6 66. 7 
(13. 2) (25. 7) (18. 6) 
33. 8 66. 3 65. 8 
(13. 7) (25. 2) (19. 9) 
4 8 . 3 82. 4 77. 3 
(15. 6) (17. 8) (20. 0) 
55. 5 90. 2 86. 2 
(15. 3) (13. 0) (16. 8) 
68. 0 95. 6 94. 3 
(17. 0) (6. 0) (7. 2) 
76. 6 98. 1 99. 0 
(17. 3) (2. 8) (0. 0) 
82. 0 98. 0 99. 0 
(16. 9) (2. 9) (0. 0) 
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Table B - 4 . Mean pure tone hearing thresholds (standard 
deviation) at frequencies above 8000 H z . 
NORMAL SUBJECTS 
AGE (years) 6-19 >20 
NUMBER (ears) 36 40 
8000 Hz (SPL) 21.8 21.4 
(7.4) (6.7) 
9000 Hz 24.3 23.3 
(7.0) (8.6) 
10000 Hz 21.4 20.6 
(7.3) (9.1) 
11000 Hz 22.9 26.0 
(6.5) (12.8) 
12000 Hz 22.9 25.6 
(5.9) (12.9) 
13000 Hz 26.1 36.2 
(6.8) (16.2) 
14000 Hz 31.0 40.6 
(10.1) (18.8) 
15000 Hz 41.1 48.2 
(17.7) (21.1) 
16000 Hz 50.0 60.5 
(21.0) (21.0) 
17000 Hz 57.5 73.1 
(20.7) (19.0) 
18000 Hz 69.6 85.5 
(21.7) (15.2) 
19000 Hz 80.7 92.3 
(19.2) (11.0) 
20000 Hz 85.8 95.1 
(15.1) (4.9) 
SPL = sound p r e s s u r e level 
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Table C . p  values for age group 6 to 19, comparison 
between cystic fibrosis patients with no drug exposure 
and normal v o l u n t e e r s , using the M a n n - W h i t n e y U  one tail 
test. 
CYSTIC FIBROSIS (n = 20) and NORMAL SUBJECTS (n = 36) 
f requency: P  < 
4000 Hz 0.209 
6000 Hz 0.205 
8000 Hz 0.496 
17000 Hz 0.496 
18000 Hz 0.395 
19000 Hz 0.156 
20000 Hz 0.231 
n = number of ears 
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Table D. p  values for age group 6 to 19, comparison 
between cystic fibrosis patients with drug exposure and 
cystic fibrosis patients with no drug exposure combined 
with normal volunteers using the one-tail Mann-Whitney U 
test. 
CYSTIC FIBROSIS (+ DRUG) and CYSTIC FIBROSIS (NO DRUG) 
(n = 24) with NORMAL SUBJECTS 
(n = 56) 
f requency: P < 
4000 Hz 0 . 189 
6000 Hz 0.282 
8000 Hz 0. 134 
17000 Hz 0.005 
18000 Hz 0.009 
19000 Hz 0.006 
20000 Hz 0.00005 
n = number of ears 
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Table B. p  values for age group 20 and older, 
comparison between cystic fibrosis patients with drug 
exposure and cystic fibrosis patients with no drug 
exposure combined with noraal v o l u n t e e r s , using the one-
tail M a n n - W h i t n e y U  test. 
CYSTIC FIBROSIS (+ DRUG) and CYSTIC FIBROSIS (NO DRUG) 
(n = 20) with NORMAL SUBJECTS 
(n = 46) 
frequency: P < 
4000 Hz 0. 001 
6000 Hz 0. 0006 
8000 Hz 0. 0001 
17000 Hz 0. 0007 
18000 Hz 0. 002 
19000 Hz 0. 004 
20000 Hz 0. 002 
n = number of ears 
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TABLE F. Nuiber/percentage of patients and subjects that did not hear at lOOdb. 
DISEASE CYSTIC FIBROSIS NORHAL SUBJECTS 
DRUG YES NO YES NO 1 NO NO 
ABE GROUP 6-19 6-19 >20 >201 6-19 >20 
n : 12 10 10 3 f 18 20 
I 
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Individual puretone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: 6 - 1 9 y e a r s age group 
aiinoglycoside 
PATIENT SEX Hz 250 250 500 500 lk lk 2k 2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
NUMBER MALE :T L R L R L R L R L R L R L R L R L R 
15 10 10 10 0 5 -5 5 10 15 0 5 0 5 5 10 25 10 
20 25 20 25 5 10 10 5 10 5 10 10 10 10 15 15 20 15 
10 10 10 10 0 0 0 0 -5 -5 5 10 -5 5 5 0 20 0 
5 10 5 5 0 0 0 0 0 0 0 0 25 15 20 15 25 15 
15 15 15 20 10 15 15 20 15 15 10 15 15 15 35 10 35 10 
15 15 10 15 5 5 0 5 0 5 -5 0 20 15 10 5 25 5 
15 20 10 15 0 5 0 5 0 5 5 5 25 10 15 10 30 10 
5 10 0 -5 -5 -5 0 0 -5 5 -10 -5 0 0 0 10 25 10 
25 25 15 25 15 15 5 10 5 10 5 0 10 5 15 5 25 5 
10 20 10 10 5 5 5 0 -10 -5 0 0 -10 0 5 0 15 0 
10 15 10 0 0 0 5 -5 5 -5 0 0 10 10 10 5 20 5 















NUMBER HALE =T 
FEMALES 
Individual pure tone hearing thresholds in decibelsfor: 
CYSTIC FIBROSIS PATIENTS: 6-19 years age group 
aiinoglycoside 
kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 

























25 35 25 25 30 25 30 
30 35 40 45 35 35 45 
20 20 15 15 20 20 15 
40 30 25 20 20 15 20 
35 30 35 35 40 25 40 
30 35 35 35 25 15 20 
25 25 20 20 20 15 20 
35 30 25 35 25 30 35 
20 15 25 20 25 50 40 
20 20 25 30 20 25 15 
30 30 20 30 25 20 25 
20 35 10 20 25 20 30 
25 35 35 25 40 50 50 60 70 70 85 85 95 85 99 
40 45 60 60 99 80 99 85 99 95 99 99 99 99 99 
30 30 40 35 30 55 40 85 60 99 65 99 90 99 95 
20 20 25 15 35 35 40 45 50 45 50 50 50 65 60 
30 45 30 45 30 45 50 60 70 80 85 90 95 99 99 
15 30 20 20 25 40 50 55 65 80 85 95 95 99 99 
20 25 35 30 30 45 40 50 50 60 55 85 70 99 85 
20 30 30 35 40 50 30 65 55 90 80 99 95 99 99 
55 50 65 45 65 75 75 90 70 99 99 99 99 99 99 
20 25 25 20 15 45 40 55 70 75 75 95 80 95 95 
15 45 30 35 35 45 40 60 60 75 85 99 99 99 99 
30 65 55 90 80 99 95 99 99 99 90 95 99 99 99 
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Individual pure tone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: 6-19 years age group 
no aiinoglycoside 
PATIENT SEX Hz 250 250 500 500 lk lk 2k 2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
NUMBER MALE =T L R L R L R L R L R L R L R L R L R 
FEMALES 
2 .F. 10 15 5 15 5 10 0 0 5 5 10 10 20 20 25 30 35 30 
5 .T. 5 10 5 10 0 5 10 5 -5 -5 0 5 5 10 0 5 15 5 
6 .T. 20 15 10 20 5 5 0 5 0 5 0 5 25 10 10 15 20 15 
12 .T. 20 25 10 10 -5 0 -5 0 -5 -5 -5 -5 -5 -5 0 5 25 5 
13 .T. 10 10 0 0 0 -10 0 0 0 10 -5 5 -10 0 -10 5 5 5 
21 .F. 10 0 5 0 5 0 0 0 0 -5 0 0 5 15 10 10 15 10 
30 .F. 10 10 10 10 0 5 -10 0 5 5 5 5 10 5 5 0 15 0 
31 .T. 15 15 5 15 5 0 10 10 -5 0 10 5 5 0 10 5 30 5 
32 .F. 10 15 0 10 0 5 -5 5 -10 -10 -5 0 0 -5 10 5 30 5 
37 .F. 15 25 15 25 15 15 15 20 15 20 10 20 15 15 10 20 30 20 
PATIENT SEX 
NUMBER MALE :T 
FEMALE-F 
Individual pure tone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: 6-19 years age group 
no aiinoglycoside 
kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 
L R L R L R L R L R L R L R L R L R L R L R 
40 35 25 25 20 20 35 25 45 25 40 30 50 70 65 80 70 99 99 99 99 99 
15 20 15 20 15 20 20 30 25 30 20 55 40 80 45 90 65 95 85 90 90 90 
30 50 25 35 30 25 35 25 30 35 25 25 35 40 60 50 70 70 75 75 99 80 
20 25 25 15 25 15 45 35 30 70 35 70 55 70 60 65 75 75 90 85 99 90 
5 15 15 25 20 30 30 40 35 45 30 30 45 45 60 55 80 75 80 85 85 90 
35 25 10 10 25 10 15 10 30 30 15 15 30 20 35 30 35 50 55 50 60 60 
15 25 20 30 25 30 25 35 30 35 35 40 40 55 50 40 50 45 60 50 65 55 
40 15 40 20 40 15 35 20 25 20 20 25 35 30 45 35 65 45 75 45 90 45 
30 15 30 30 45 30 35 20 30 25 25 25 55 70 60 75 85 85 99 95 99 95 
35 30 25 30 30 40 30 30 35 35 40 50 50 50 55 55 60 65 70 70 75 75 
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Individual pure tone hearing thresholds in decibels for: 
NORMAL SUBJECTS: 6-19 years age group 
SUBJECT SEX Hz 250 250 500 500 lk lk 2k 2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
NUMBER MALE =T L R L R L R L R L R L R L R L R L R 
FEMALES 
25 25 25 25 15 20 5 0 
10 5 5 5 5 0 0 0 
10 5 10 10 5 10 5 5 
10 10 0 15 0 -5 5 0 
10 10 10 10 0 0 10 0 
10 5 5 5 5 5 5 0 
20 5 15 10 0 5 0 0 
5 10 5 10 0 5 -5 0 
15 10 5 15 0 5 - 5 5 
5 5 5 10 0 0 0 5 
10 15 10 10 0 10 0 0 
10 10 5 10 0 5 -5 -5 
20 15 10 15 0 0 -5 5 
15 20 5 15 5 5 5 0 
0 5 -5 0 0 5 0 0 
15 10 5 5 0 0 0 -5 
10 10 5 5 0 -5 5 5 
15 10 15 15 10 5 5 0 
5 0 5 0 10 10 5 15 20 15 
0 0 5 0 5 15 5 15 5 15 
5 0 5 0 20 10 30 35 35 35 
5 0 -5 -5 5 5 5 0 20 0 
5 5 10 5 15 10 20 5 20 5 
0 5 0 5 -5 5 0 0 20 0 
0 10 0 5 0 5 0 10 15 10 
-5 5 -5 5 0 5 5 5 25 5 
5 0 5 5 10 10 5 5 25 5 
5 5 5 0 15 10 0 0 20 0 
0 0 10 5 10 15 5 5 15 5 
0 0 0 5 0 5 -5 10 15 10 
0 5 -10 10 15 10 10 5 20 5 
5 10 5 5 5 15 20 15 35 15 
0 5 10 10 5 10 10 0 25 0 
10 15 15 10 15 5 15 15 25 15 
10 5 15 10 10 5 5 10 20 10 
10 -5 5 10 2 20 25 15 35 15 
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Individual pure tone hearing thresholds in decibels for: 
NORMAL SUBJECTS: 6-19 years age group 
SUBJECT SEX kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 
NUMBER MALE =T L R L R L R L R L R L R L R L R L R L R L R 
FEMALE-F 
17 .F. 25 25 20 15 35 30 25 30 35 40 50 85 99 95 95 99 99 95 99 95 99 95 
18 .F. 15 30 20 25 25 25 25 25 30 20 35 30 35 30 45 30 45 40 40 40 50 45 
25 .F. 40 35 35 30 25 20 15 15 25 20 20 15 40 20 50 45 65 60 70 70 75 70 
19 .F. 25 10 25 10 25 10 30 15 35 20 20 25 25 25 30 30 35 35 40 45 45 65 
31 .F. 20 20 15 15 10 25 15 25 20 35 25 25 65 30 70 35 75 35 80 70 85 85 
8 .F. 25 20 25 25 30 20 25 25 20 20 20 40 30 40 40 35 40 40 65 75 90 95 
26 .F. 20 20 20 10 20 15 20 10 25 15 30 30 30 30 35 45 70 70 90 90 90 90 
28 .F. 35 35 35 35 30 25 20 30 35 25 40 50 80 60 90 65 95 99 99 99 95 95 
27 .F. 25 20 25 10 30 25 25 25 35 25 40 45 35 50 50 45 80 60 95 85 95 95 
29 .F. 35 25 20 20 25 25 25 25 25 30 25 45 45 60 45 70 80 95 99 99 99 95 
11 .F. 15 25 20 20 15 25 20 25 25 25 30 30 65 40 50 50 95 65 99 90 99 90 
12 .F. 25 20 35 25 30 25 35 25 25 25 25 55 75 70 75 75 90 90 99 90 95 95 
13 .F. 30 25 35 20 40 20 30 10 35 30 30 30 60 40 95 50 99 55 99 60 99 70 
32 .F. 20 30 15 20 20 25 20 25 20 15 25 30 35 45 55 60 70 65 75 70 80 75 
33 .T. 25 20 15 15 20 15 15 15 25 20 40 30 40 35 50 35 50 50 70 90 80 90 
34 .F. 35 20 15 25 20 15 25 25 30 20 30 25 50 35 65 40 60 50 75 55 90 85 
3 .T. 15 15 15 15 15 20 25 25 35 35 55 70 80 85 80 95 95 95 99 99 95 95 
4 .F. 30 20 25 20 25 20 30 25 25 15 30 35 60 60 70 75 75 90 90 99 99 99 
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PATIENT SEX 
NUMBER HALE -T 
FEMALES 
Individual pure tone hearing thresholds in d e c i b e l s f o r : 
CYSTIC FIBROSIS PATIENTS: years age group 
aiinoglycoside 
Hz 250 250 500 500 lk lk 2k 2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
L R L R L R L R L R L R L R L R L R 
10 10 10 10 5 5 20 20 25 25 10 20 25 20 10 10 30 10 
15 5 15 5 5 5 0 0 -10 -10 5 0 10 10 10 0 20 0 
20 15 15 10 0 5 10 5 15 0 10 10 15 30 25 35 45 35 
15 15 5 0 -5 0 0 0 0 -10 0 0 20 0 10 -10 35 -10 
15 15 10 15 10 10 10 0 5 5 20 20 15 15 15 10 35 10 
15 15 25 15 15 10 25 20 10 0 20 15 80 15 80 20 90 20 
20 15 15 15 10 10 15 10 15 5 15 5 15 15 25 25 40 25 
20 10 10 10 5 5 10 5 5 0 5 5 10 15 10 15 25 15 
15 20 10 15 5 5 10 5 20 20 20 15 35 15 30 20 45 20 
20 20 15 30 40 55 99 99 99 99 99 99 99 99 99 99 99 99 
Individual pure tone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: >= 20 years age group 
no aainoglycoside 
PATIENT SEX Hz 250 250 500 500 lk lk 2k 2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
NUMBER MALE =T L R L R L R L R L R L R L R L R L R 
FEMALES 
10 .F. 10 10 5 5 0 5 0 5 0 0 5 5 15 20 0 5 20 5 
15 .T. 20 15 20 15 0 10 5 0 10 5 10 20 45 40 30 25 35 25 
16 .T. 15 15 0 5 5 0 0 0 15 15 15 30 5 30 10 0 10 0 
Individual pure tone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: years age group 
a i i n o g y c o s i d e 
PATIENT SEX kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 
NUMBER MALE -1 L R L R L R L R L R L R L R L R L R L R L R 
FEMALES 
1 .T. 25 10 10 5 15 15 15 20 30 40 40 35 65 50 70 60 80 85 90 90 90 90 
4 .F. 35 25 10 25 30 15 25 25 25 30 35 25 60 55 90 70 90 85 99 99 99 95 
14 .F. 25 25 10 25 25 30 35 30 40 45 40 55 70 90 70 99 95 99 99 99 99 99 
18 .T. 15 20 20 15 15 20 20 25 30 25 35 60 75 75 90 85 90 99 99 99 99 99 
23 .F. 30 30 40 45 45 30 45 35 60 50 80 80 99 99 99 99 99 99 99 99 99 99 
29 .F. 95 95 95 90 99 95 99 95 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
25 .T. 65 50 45 40 40 35 45 40 70 55 75 65 95 90 99 99 99 99 99 99 99 99 
17 .F. 25 25 30 30 40 40 45 35 45 55 55 75 95 99 99 99 99 99 99 99 99 99 
24 .T. 25 25 25 25 40 25 65 25 50 35 55 40 80 55 99 80 99 99 99 99 99 99 
38 .F. 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
Individual pure tone hearing thresholds in decibels for: 
CYSTIC FIBROSIS PATIENTS: >: 20 years age group 
no aiinogiycoside 
PATIENT SEX kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 
NUMBER MALE :T L R L R L R L R L R L R L R L R L R L R L R 
FEMALES 
10 .F. 30 35 35 45 30 35 30 55 50 55 50 75 90 99 99 99 99 99 99 99 99 99 
15 .T. 60 40 70 45 85 85 90 85 95 95 85 95 75 90 90 99 99 99 99 99 99 99 
16 .T. 30 25 30 35 25 45 20 60 25 70 55 50 65 45 65 65 85 85 99 99 99 99 
40 
Individual pure to 
NORMAL SUB 
SUBJECT SEX Hz 250 250 500 500 lk lk 2k 
NUMBER MALE :T L R L R L R L 
FEMALES 
23 .F. 20 15 10 5 5 5 5 
21 .F. 0 5 10 5 0 0 0 
36 .F. 10 20 10 -5 10 0 15 
14 .F. 15 15 5 10 0 5 0 
15 .F. 15 20 5 30 5 15 0 
16 .F. 10 10 10 10 0 5 5 
35 .F. 15 10 5 15 -5 0 5 
3? .F. 15 15 10 10 0 5 10 
10 .F. 10 10 10 10 0 0 0 
6 .F. 10 5 10 5 0 5 5 
1 .F. 0 10 0 0 -5 -5 -10 
22 .F. 5 5 0 5 5 0 0 
30 .F. 10 10 5 0 0 0 5 
7 .F. -10 -10 - 5 - 5 0 5 0 
9 .F. 0 5 5 10 5 15 5 
38 .F. 10 10 5 5 0 5 0 
2 .F. 10 5 10 5 -5 -5 -10 
24 .F. 10 20 0 5 5 5 5 
20 .F. 10 10 10 15 5 5 0 
5 .T. 20 15 10 5 0 0 5 
e hearing thresholds in decibels for: 
ECTS: ): 20 years age group 
2k 3k 3k 4k 4k 6k 6k 8k 8k SPL 8k 8k 
R L R L R L R L R L R 
10 15 5 15 5 10 10 15 20 15 20 
0 0 -10 0 -5 5 -5 10 5 20 5 
-5 20 -5 15 -5 20 0 10 5 15 5 
0 0 5 0 10 5 10 0 0 20 0 
5 0 10 0 5 5 10 5 5 15 5 
0 -10 -5 5 0 5 10 -10 10 10 10 
0 5 5 15 0 15 5 5 10 25 10 
0 20 0 25 10 15 15 10 5 15 5 
0 5 0 0 0 0 -10 -5 -5 10 -5 
0 0 0 5 0 10 10 20 10 30 10 
-5 5 -5 -5 -5 5 -5 -10 -5 25 -5 
0 0 0 0 5 5 10 0 0 15 0 
5 2 0 10 15 15 20 20 15 25 15 
5 0 0 -5 -5 5 0 5 5 25 5 
5 -5 -5 5 5 10 15 5 15 20 15 
5 5 5 -5 5 5 10 5 5 20 5 
-10 10 5 5 -5 15 0 10 -5 20 -5 
5 0 10 -5 10 35 20 30 15 30 15 
0 10 5 25 -10 35 5 0 -10 30 -10 
0 0 0 0 0 0 0 5 0 25 0 
4 1 
Individual pure tone hearing thresholds in decibels for: 
NORMAL SUBJECTS: >: 20 years age group 
SUBJECT SEX kHz 9k 9 10 10 11 11 12 12 13 13 14 15 16 16 17 17 18 18 19 19 20 20 
NUMBER MALE =T L R L R L R L R L R L R L R L R L R L R L R 
FEMALE=F 
23 .F. 30 30 10 25 10 15 25 20 25 30 35 30 35 35 55 50 70 70 90 80 90 95 
21 .F. 25 20 15 15 15 10 10 5 20 20 20 25 60 35 75 65 85 95 95 90 95 90 
36 .F. 30 20 25 30 30 25 40 25 60 35 40 40 60 40 85 70 90 85 99 90 99 99 
14 .F. 30 25 15 20 30 25 25 25 30 25 40 50 60 70 70 70 90 90 99 99 99 99 
15 .F. 15 45 20 10 25 15 25 15 25 15 20 35 35 30 35 45 50 60 60 85 95 90 
16 .F. 35 35 10 10 30 25 20 15 25 25 30 30 50 50 55 60 95 90 99 99 95 99 
35 .F. 25 15 20 25 25 35 25 30 30 30 30 40 60 55 55 60 65 60 99 99 95 99 
37 .F. 15 25 50 30 70 50 70 40 75 60 80 90 99 99 99 99 99 99 99 99 99 99 
10 .F. 20 15 0 20 10 10 10 10 30 20 30 25 15 25 30 40 45 50 55 60 80 85 
6 .F. 20 10 20 25 15 20 35 35 55 50 65 75 80 70 85 99 95 99 99 99 99 99 
1 .F. 20 15 10 25 20 20 25 20 50 65 45 75 70 80 85 95 90 99 95 99 99 99 
22 .F. 25 20 25 20 25 25 15 15 25 20 30 45 60 75 90 85 99 95 99 95 99 99 
30 .F. 20 30 25 25 35 40 45 50 70 65 75 95 99 99 99 99 99 99 99 99 99 99 
7 .F. 30 25 25 25 30 25 25 30 45 35 45 45 60 60 70 90 90 95 90 95 99 95 
9 .F. 25 40 15 25 10 25 15 15 20 15 50 70 65 70 75 70 80 80 85 90 90 90 
38 .F. 25 0 40 30 50 30 50 35 50 35 50 45 85 70 99 80 99 99 99 99 99 99 
2 .F. 20 15 20 15 30 30 20 20 35 30 25 50 65 65 75 70 90 85 90 95 85 99 
24 .F. 30 10 20 30 45 40 35 30 40 40 45 40 70 50 85 55 99 90 99 99 95 95 
20 .F. 25 25 15 10 20 25 20 20 20 25 20 30 70 35 75 80 90 85 95 95 90 95 




Trimmed two tail t-test statistics: Evaluation of 
differences between left and right ears for individual 
f requenc ies. 
sample size 
NORMAL SUBJECTS CYSTIC FIBROSIS 
= 38 35 
FREQUENCY t-STAT. /"-VALUE t-STAT . jP-VALUE 
250 hZ -0.17 0. 87 -0.15 0. 88 
500 - 2 . 19 0.04 -1.58 0. 12 
1000 -2.27 0. 03 - 2 . 20 0. 04 
2000 0.46 0.65 0.15 0 . 89 
3000 1.08 0.29 0.44 0.67 
4000 0. 92 0. 37 -2.44 0.02 
6000 1.18 0. 25 0. 87 0 . 39 
8000 0. 68 0.50 2.00 0.05 
8000 (HFA) - 0 . 26 0. 80 0.71 0.48 
9000 1.90 0.07 0.78 0.44 
10000 0.64 0.53 - 0 . 97 0. 34 
11000 1.88 0 . 07 1.08 0.29 
12000 2. 15 0. 04 0. 50 0. 62 
13000 3. 24 0.01 - 0 . 93 0.36 
14000 0. 84 0.40 -0.79 0.43 
15000 0. 96 0.34 -1 . 00 0. 32 
16000 2. 25 0.03 -1.13 0.27 
17000 1.48 0. 15 - 0 . 64 0.53 
18000 1. 78 0.08 - 1 . 03 0.31 
19000 1.00 0.33 1.86 0. 07 
20000 -0.18 0. 86 2. 24 0.03 




HIGH FREQUENCY HEARING IN PATIENTS WITH CYSTIC 
FIBROSIS RECEIVING AMINOGLYCOSIDE THERAPY 
You are being asked to participate in a study that will 
involve testing your h e a r i n g . You may have received 
antibiotics that belong to a group called 
a m i n o g l y c o s i d e s . These agents have been known to cause 
hearing loss. The reason we want to perform this study 
is to see if we can find out if the total amount of 
aminoglycoside you have ever received has anything to 
do with your h e a r i n g . 
The hearing test will involve sitting in a sound-proof 
room with earphones on and listening to some tones. You 
will just let the person testing your hearing know when 
you hear the sounds. The test is painless and cannot 
harm you. The person who does the test will explain to 
you what he finds out about your hearing when the test 
is over. Depending upon your age, the whole process 
should take around 45 minutes to 1 h o u r . The testing 
will take place in clinic 9 of the University hospital. 
When you receive your hearing t e s t , a middle ear 
infection may be n o t i c e d , even though you have no pain 
in your ears. Even though this infection may not bother 
you it may change your hearing test r e s u l t s . If this 
should happen to y o u , you will be asked to have the test 
repeated the next time you return to clinic or in 
approximately two to three w e e k s . It is important to 
test your hearing when you do not have any ear 
infection. 
If you have ever received aminoglycosides we will also 
look through your medical records to find out how much 
of these drugs you have received in your lifetime. 
Every effort will be m a d e to keep all of your records 
private to protect your identity. In the event that 
this research is p u b l i s h e d , your name will not be used. 
If you have any questions at this time, please feel free 
to ask them. If you decide to p a r t i c i p a t e in the study 
and have any questions at a later time, you should 
contact Teresa M c R o r i e , R . P h . or John B o s s o , P h a r m . D . at 
5 8 1 - 5 9 8 4 . 
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If you have any questions regarding this study which you 
would rather not discuss with the people who are 
performing the p r o j e c t , you are are free to call the 
office of the Institutional Review B o a r d , 581-3655. 
I understand that participation in this study is my own 
choice and that I may decide not to participate at any 
time. If I decide not to p a r t i c i p a t e , it will not 
affect the quality of care that I r e c e i v e . A copy of 
this consent form has been given to m e . 
Patient Date 
Parent or Guardian Witness 
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